CytoDyn Announces Vyrologix as Proprietary Name fo
Post# of 153898
(Total Views: 820)
Posted On: 04/27/2020 9:21:30 AM
CytoDyn Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United States
Download as PDFApril 27, 2020 9:20am EDT
Company appoints Interim Chief Financial Officer
VANCOUVER, Washington, April 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced conditional acceptance by the U.S. Food and Drug Administration (FDA) of the proprietary name Vyrologix (pronounced - vie-ro-loj-iks) for leronlimab as a combination therapy for highly treatment experienced HIV patients in the United States. In addition, the Company has also received a notice of allowance from the U.S. Trademark Office for the Vyrologix mark.
Final approval of Vyrologix as the proprietary name for leronlimab is conditional on FDA approval of the Company’s Biologics License Application and new drug application.
“We are pleased to receive the FDA’s conditional acceptance of Vyrologix as the proprietary name for leronlimab’s combination therapy treatment of HIV,” said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn. “This acceptance builds on the exceptional results from our clinical trials and our collaboration with Vyera Pharmaceuticals to commercialize and market this potential treatment to fulfill the unmet needs of HIV patients. We are also excited about the stylized Vyrologix mark and logo, which we will share immediately upon acceptance of our U.S. trademark application.”
The Company also announced the appointment of Michael D. Mulholland as Interim Chief Financial Officer, who most recently served as Executive Advisor to the CEO and Senior Vice President-Finance. Mr. Mulholland joined the Company in December 2012 and served as Chief Financial Officer, Treasurer and Corporate Secretary until November 2019.
Dr. Pourhassan, stated, “We are pleased to have Mike return to a senior leadership role. His deep experience and knowledge will help us navigate through the myriad of opportunities before us and assist our team to maximize shareholder value.”
Download as PDFApril 27, 2020 9:20am EDT
Company appoints Interim Chief Financial Officer
VANCOUVER, Washington, April 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced conditional acceptance by the U.S. Food and Drug Administration (FDA) of the proprietary name Vyrologix (pronounced - vie-ro-loj-iks) for leronlimab as a combination therapy for highly treatment experienced HIV patients in the United States. In addition, the Company has also received a notice of allowance from the U.S. Trademark Office for the Vyrologix mark. Final approval of Vyrologix as the proprietary name for leronlimab is conditional on FDA approval of the Company’s Biologics License Application and new drug application.
“We are pleased to receive the FDA’s conditional acceptance of Vyrologix as the proprietary name for leronlimab’s combination therapy treatment of HIV,” said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn. “This acceptance builds on the exceptional results from our clinical trials and our collaboration with Vyera Pharmaceuticals to commercialize and market this potential treatment to fulfill the unmet needs of HIV patients. We are also excited about the stylized Vyrologix mark and logo, which we will share immediately upon acceptance of our U.S. trademark application.”
The Company also announced the appointment of Michael D. Mulholland as Interim Chief Financial Officer, who most recently served as Executive Advisor to the CEO and Senior Vice President-Finance. Mr. Mulholland joined the Company in December 2012 and served as Chief Financial Officer, Treasurer and Corporate Secretary until November 2019.
Dr. Pourhassan, stated, “We are pleased to have Mike return to a senior leadership role. His deep experience and knowledge will help us navigate through the myriad of opportunities before us and assist our team to maximize shareholder value.”
(2)
(0)